Eun-Jung Lee

This inventor holds 6 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Yuhan Corporation, Abl Bio Inc., Snu Rdb Foundation. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eun-Jung Lee. Retrieved from https://idiyas.com/inventor/eun-jung-lee-ex238lpd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 83.3

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 8.8

ph-index = 1

Forward Citations = 781(Granted Patents)

Company Filing History:

The Catholic University of Korea

patents

5. 1 out of 1

The Catholic University of Korea Industry-Academic Cooperation Foundation, Catholic Univ. of Korea Songeui Campus

patent

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

2. 12168690 - Anti-EGFR/anti-4-1BB bispecific antibody (2024-12-17),

3. 11505603 - Anti-TIGIT antibodies and uses thereof (2022-11-22),

4. 10851346 - MTOR/STAT3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders (2020-12-01),

5. 9526717 - Composition for treating immune diseases containing daurinol compound as active ingredient (2016-12-27),

6. 8734831 - Method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor (2014-05-27),

Title: Innovator Eun-Jung Lee: Pioneering Bispecific Antibody Treatments

Introduction

Eun-Jung Lee, a distinguished inventor based in Gyeonggi-do, South Korea, has made significant strides in the field of biopharmaceuticals. With a remarkable portfolio of six patents, Lee's work focuses on developing innovative treatment methods for cancer through bispecific antibodies, demonstrating a commitment to advancing medical technology.

Latest Patents

Among Lee's noteworthy patents is the "Anti-HER2/anti-4-1BB bispecific antibody and use thereof." This invention encompasses a pharmaceutical composition and a method aimed at treating and preventing cancer by leveraging a bispecific antibody targeting both HER2 and 4-1BB pathways. Another significant patent is the "Anti-EGFR/anti-4-1BB bispecific antibody," which also provides a creative strategy for cancer treatment through a dual-targeting approach involving EGFR and 4-1BB.

Career Highlights

Eun-Jung Lee has been affiliated with renowned companies, such as Yuhan Corporation and Abl Bio Inc., where he has honed his skills and contributed to groundbreaking research. His expertise in antibody development has positioned him as a leader in the biopharmaceutical industry, pushing the boundaries of what is possible in cancer treatment.

Collaborations

Throughout his career, Lee has collaborated with notable colleagues like Moo Young Song and Na Rae Lee, working together to advance their shared vision of innovative medical solutions. These collaborations have fostered an environment of creativity and mutual support, driving collective success in their projects.

Conclusion

Eun-Jung Lee's contributions to the field of bispecific antibody research are profound. With six patents to his name and significant collaborations, he continues to inspire next-generation innovations in cancer treatment. His work not only highlights the importance of collaboration in scientific research but also serves to pave the way for future advancements in medical therapies.

Profile summary based on public USPTO records.